NASDAQ:NVUS - Novus Therapeutics Stock Price, Price Target & More

$4.85 +0.17 (+3.63 %)
(As of 04/20/2018 04:00 PM ET)
Previous Close$4.85
Today's Range$4.69 - $4.95
52-Week Range$3.12 - $6.60
Volume23,749 shs
Average Volume26,055 shs
Market Capitalization$44.03 million
P/E RatioN/A
Dividend YieldN/A
Beta0.16

About Novus Therapeutics (NASDAQ:NVUS)

Novus Therapeutics logoNovus Therapeutics, Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of ear, nose, and throat products. Its lead product is a nasally-administered combination drug product (OP-02) intended to address the underlying cause of otitis media and Eustachian tube dysfunction (OM/ETD) conditions. The company also has a foam-based drug delivery technology platform (OP-01) that could be used to deliver drugs into the ear, nose, and sinus cavities. It is developing a foam-based combination drug-product to the external ear canal that is an improved treatment option for acute otitis externa. The company is headquartered in Irvine, California.

Receive NVUS News and Ratings via Email

Sign-up to receive the latest news and ratings for NVUS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NVUS
CUSIPN/A
Phone949-238-8090

Debt

Debt-to-Equity RatioN/A
Current Ratio13.19%
Quick Ratio13.19%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.75 per share
Price / Book1.76

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-13,110,000.00
Net MarginsN/A
Return on Equity-71.86%
Return on Assets-64.63%

Miscellaneous

Employees7
Outstanding Shares9,410,000

How to Become a New Pot Stock Millionaire

Novus Therapeutics (NASDAQ:NVUS) Frequently Asked Questions

What is Novus Therapeutics' stock symbol?

Novus Therapeutics trades on the NASDAQ under the ticker symbol "NVUS."

How were Novus Therapeutics' earnings last quarter?

Novus Therapeutics (NASDAQ:NVUS) announced its quarterly earnings results on Wednesday, November, 8th. The biopharmaceutical company reported ($0.43) earnings per share for the quarter. View Novus Therapeutics' Earnings History.

What price target have analysts set for NVUS?

1 brokerages have issued twelve-month price objectives for Novus Therapeutics' stock. Their forecasts range from $7.00 to $7.00. On average, they anticipate Novus Therapeutics' share price to reach $7.00 in the next year. View Analyst Ratings for Novus Therapeutics.

Who are some of Novus Therapeutics' key competitors?

Who are Novus Therapeutics' key executives?

Novus Therapeutics' management team includes the folowing people:
  • Mr. Gregory J. Flesher, CEO & Director (Age 48)
  • Dr. Catherine C. Turkel PharmD, MBA, Ph.D., Pres (Age 57)
  • Mr. Jon Kuwahara CPA, Sr. VP of Fin. & Admin. (Age 53)
  • Ms. Christine G. Ocampo CPA, Consultant (Age 46)

Has Novus Therapeutics been receiving favorable news coverage?

News articles about NVUS stock have trended somewhat positive recently, according to Accern Sentiment. The research firm identifies positive and negative media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Novus Therapeutics earned a media sentiment score of 0.02 on Accern's scale. They also assigned media headlines about the biopharmaceutical company an impact score of 46.28 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

How do I buy shares of Novus Therapeutics?

Shares of NVUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Novus Therapeutics' stock price today?

One share of NVUS stock can currently be purchased for approximately $4.85.

How big of a company is Novus Therapeutics?

Novus Therapeutics has a market capitalization of $44.03 million. Novus Therapeutics employs 7 workers across the globe.

How can I contact Novus Therapeutics?

Novus Therapeutics' mailing address is 19900 MACARTHUR BOULEVARD SUITE 550, IRVINE CA, 92612. The biopharmaceutical company can be reached via phone at 949-238-8090 or via email at [email protected]


MarketBeat Community Rating for Novus Therapeutics (NVUS)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  117 (Vote Outperform)
Underperform Votes:  117 (Vote Underperform)
Total Votes:  234
MarketBeat's community ratings are surveys of what our community members think about Novus Therapeutics and other stocks. Vote "Outperform" if you believe NVUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVUS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Novus Therapeutics (NASDAQ:NVUS) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
1 Wall Street analysts have issued ratings and price targets for Novus Therapeutics in the last 12 months. Their average twelve-month price target is $7.00, suggesting that the stock has a possible upside of 44.33%. The high price target for NVUS is $7.00 and the low price target for NVUS is $7.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyN/AN/A
Consensus Rating Score: 3.003.00N/AN/A
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $7.00$7.00N/AN/A
Price Target Upside: 44.33% upside124.36% upsideN/AN/A

Novus Therapeutics (NASDAQ:NVUS) Consensus Price Target History

Price Target History for Novus Therapeutics (NASDAQ:NVUS)

Novus Therapeutics (NASDAQ:NVUS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/13/2018Ascendiant Capital MarketsInitiated CoverageBuy -> Buy$7.00HighView Rating Details
8/24/2016BMO Capital MarketsReiterated RatingMarket Perform$1.70 -> $1.15N/AView Rating Details
8/10/2016William BlairReiterated RatingNeutralN/AView Rating Details
7/28/2016Bank of AmericaDowngradeNeutral -> UnderperformN/AView Rating Details
7/26/2016Stifel NicolausDowngradeBuy -> HoldN/AView Rating Details
7/26/2016Janney Montgomery ScottDowngradeBuy -> NeutralN/AView Rating Details
7/26/2016Wells FargoDowngradeOutperform -> Market PerformN/AView Rating Details
(Data available from 4/21/2016 forward)

Earnings

Novus Therapeutics (NASDAQ:NVUS) Earnings History and Estimates Chart

Earnings by Quarter for Novus Therapeutics (NASDAQ:NVUS)

Novus Therapeutics (NASDAQ NVUS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017Q3 2017($0.43)ViewN/AView Earnings Details
8/9/2017Q2 2017($2.70)($1.32)ViewN/AView Earnings Details
11/3/2016Q3 2016($4.14)($3.69)ViewN/AView Earnings Details
8/4/2016Q2 2016($4.86)($5.40)ViewN/AView Earnings Details
5/10/2016Q1($0.50)($0.51)ViewN/AView Earnings Details
3/10/2016Q4($0.47)($0.49)ViewN/AView Earnings Details
11/10/2015Q3($0.5270)($0.53)$6.03 millionViewN/AView Earnings Details
8/12/2015Q215($0.50)($0.40)ViewN/AView Earnings Details
5/12/2015Q115($0.31)($0.59)ViewN/AView Earnings Details
3/12/2015($0.40)($0.28)ViewN/AView Earnings Details
11/10/2014($0.42)($2.71)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Novus Therapeutics (NASDAQ:NVUS) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Novus Therapeutics (NASDAQ NVUS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.20%
Institutional Ownership Percentage: 32.79%
Insider Trading History for Novus Therapeutics (NASDAQ:NVUS)

Novus Therapeutics (NASDAQ NVUS) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/10/2017Catherine C. TurkelInsiderBuy11,111$9.99$110,998.89View SEC Filing  
5/10/2017Gregory J. FlesherCEOBuy58,959$9.99$589,000.41View SEC Filing  
3/15/2016Stephen Jr. BuckleyDirectorBuy8,000$5.74$45,920.0011,000View SEC Filing  
11/11/2015Stephen Jr. BuckleyDirectorBuy3,000$11.25$33,750.003,000View SEC Filing  
9/21/2015John S. McbrideCOOSell13,500$14.01$189,135.00View SEC Filing  
9/8/2015Lee KalowskiCFOSell4,668$13.13$61,290.8440,953View SEC Filing  
9/2/2015Lee KalowskiCFOSell2,158$12.96$27,967.6845,621View SEC Filing  
7/15/2015Bioventures Ltd NovartisMajor ShareholderSell3,566$14.26$50,851.16View SEC Filing  
7/14/2015Bioventures Ltd NovartisMajor ShareholderSell27,861$14.41$401,477.01View SEC Filing  
7/13/2015Bioventures Ltd NovartisMajor ShareholderSell20,611$14.20$292,676.20View SEC Filing  
6/29/2015Jodie Pope MorrisonCEOSell16,000$13.77$220,320.00View SEC Filing  
6/24/2015John S McbrideCOOSell9,000$14.01$126,090.00View SEC Filing  
6/23/2015John S McbrideCOOSell6,700$14.00$93,800.00View SEC Filing  
6/22/2015John S McbrideCOOSell2,000$14.02$28,040.00View SEC Filing  
6/16/2015Bioventures Ltd NovartisMajor ShareholderSell1,120$14.27$15,982.40View SEC Filing  
6/11/2015Bioventures Ltd NovartisMajor ShareholderSell27,875$14.20$395,825.00View SEC Filing  
4/16/2015Lee KalowskiCFOSell4,567$13.00$59,371.00View SEC Filing  
4/2/2015Lee KalowskiCFOSell2,258$11.45$25,854.10View SEC Filing  
3/19/2015Bioventures Ltd NovartisMajor ShareholderSell49,141$14.50$712,544.50View SEC Filing  
9/22/2014Apple Tree Partners Ii - AnnexDirectorBuy237,500$15.00$3,562,500.00View SEC Filing  
9/22/2014Bioventures Ltd NovartisMajor ShareholderBuy325,000$15.00$4,875,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Novus Therapeutics (NASDAQ NVUS) News Headlines

Source:
DateHeadline
Novus Therapeutics (NVUS) Upgraded to Hold by Zacks Investment ResearchNovus Therapeutics (NVUS) Upgraded to Hold by Zacks Investment Research
www.americanbankingnews.com - April 18 at 8:34 PM
Novus Therapeutics, Inc (NVUS) PT Raised to $7.50 at Ascendiant CapitalNovus Therapeutics, Inc (NVUS) PT Raised to $7.50 at Ascendiant Capital
www.streetinsider.com - April 9 at 9:43 AM
Novus Therapeutics (NVUS) Lifted to Sell at ValuEngineNovus Therapeutics (NVUS) Lifted to Sell at ValuEngine
www.americanbankingnews.com - April 3 at 11:11 AM
Novus Therapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate UpdateNovus Therapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - April 2 at 9:56 AM
Novus Therapeutics (NVUS) Stock Rating Lowered by ValuEngineNovus Therapeutics (NVUS) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - March 14 at 11:22 PM
Analyzing Novus Therapeutics (NVUS) & Catalyst Biosciences (CBIO)Analyzing Novus Therapeutics (NVUS) & Catalyst Biosciences (CBIO)
www.americanbankingnews.com - February 14 at 3:18 AM
Novus Therapeutics (NVUS) Coverage Initiated at Ascendiant Capital MarketsNovus Therapeutics (NVUS) Coverage Initiated at Ascendiant Capital Markets
www.americanbankingnews.com - February 13 at 11:08 AM
Catalyst Biosciences (CBIO) & Novus Therapeutics (NVUS) Head to Head SurveyCatalyst Biosciences (CBIO) & Novus Therapeutics (NVUS) Head to Head Survey
www.americanbankingnews.com - February 5 at 9:14 PM
Novus Therapeutics (NVUS) Lifted to "Sell" at ValuEngineNovus Therapeutics (NVUS) Lifted to "Sell" at ValuEngine
www.americanbankingnews.com - February 4 at 7:40 PM
Should You Invest In The Healthcare Stock Novus Therapeutics Inc (NASDAQ:NVUS)?Should You Invest In The Healthcare Stock Novus Therapeutics Inc (NASDAQ:NVUS)?
finance.yahoo.com - January 6 at 9:06 AM
Head-To-Head Survey: Novus Therapeutics (NVUS) and 3SBio (SSRX)Head-To-Head Survey: Novus Therapeutics (NVUS) and 3SBio (SSRX)
www.americanbankingnews.com - January 2 at 9:14 PM
Comparing Alimera Sciences (ALIM) and Novus Therapeutics (NVUS)Comparing Alimera Sciences (ALIM) and Novus Therapeutics (NVUS)
www.americanbankingnews.com - December 29 at 11:30 PM
Analyzing Argos Therapeutics (ARGS) and Novus Therapeutics (NVUS)Analyzing Argos Therapeutics (ARGS) and Novus Therapeutics (NVUS)
www.americanbankingnews.com - December 18 at 5:24 AM
Tokai Pharmaceuticals (NVUS) & Its Rivals Critical ReviewTokai Pharmaceuticals (NVUS) & Its Rivals Critical Review
www.americanbankingnews.com - December 1 at 5:39 AM
Tokai Pharmaceuticals (NVUS) vs. Its Peers Head-To-Head ContrastTokai Pharmaceuticals (NVUS) vs. Its Peers Head-To-Head Contrast
www.americanbankingnews.com - November 24 at 7:20 PM
Who Are The Largest Shareholders In Novus Therapeutics Inc (NVUS)?Who Are The Largest Shareholders In Novus Therapeutics Inc (NVUS)?
finance.yahoo.com - November 22 at 6:19 AM
Novus Therapeutics to Present at the 29th Annual Piper Jaffray Healthcare ConferenceNovus Therapeutics to Present at the 29th Annual Piper Jaffray Healthcare Conference
finance.yahoo.com - November 22 at 6:19 AM
Comparing Tokai Pharmaceuticals (NVUS) and The CompetitionComparing Tokai Pharmaceuticals (NVUS) and The Competition
www.americanbankingnews.com - November 18 at 7:40 AM
Tokai Pharmaceuticals, Inc. (NVUS) Posts Quarterly  Earnings ResultsTokai Pharmaceuticals, Inc. (NVUS) Posts Quarterly Earnings Results
www.americanbankingnews.com - November 10 at 7:08 PM
Comparing Tokai Pharmaceuticals (NVUS) & KalVista Pharmaceuticals (KALV)Comparing Tokai Pharmaceuticals (NVUS) & KalVista Pharmaceuticals (KALV)
www.americanbankingnews.com - November 9 at 7:58 AM
Novus Therapeutics Reports Third Quarter 2017 ResultsNovus Therapeutics Reports Third Quarter 2017 Results
finance.yahoo.com - November 9 at 7:52 AM
Novus Therapeutics Announces the Promotion of Dr. Catherine Turkel to PresidentNovus Therapeutics Announces the Promotion of Dr. Catherine Turkel to President
finance.yahoo.com - November 7 at 7:58 AM
Analyzing KalVista Pharmaceuticals (KALV) & Tokai Pharmaceuticals (NVUS)Analyzing KalVista Pharmaceuticals (KALV) & Tokai Pharmaceuticals (NVUS)
www.americanbankingnews.com - October 23 at 12:08 AM
What’s The Outlook For Loss-Making Novus Therapeutics Inc (NVUS)?What’s The Outlook For Loss-Making Novus Therapeutics Inc (NVUS)?
finance.yahoo.com - October 5 at 1:00 PM
Analyzing Novus Therapeutics (NVUS) and Syros Pharmaceuticals (SYRS)Analyzing Novus Therapeutics (NVUS) and Syros Pharmaceuticals (SYRS)
www.americanbankingnews.com - September 14 at 2:22 AM
Critical Contrast: Tokai Pharmaceuticals (NVUS) and ChemoCentryx (CCXI)Critical Contrast: Tokai Pharmaceuticals (NVUS) and ChemoCentryx (CCXI)
www.americanbankingnews.com - August 18 at 12:22 AM
Novus Therapeutics Reports Second Quarter 2017 ResultsNovus Therapeutics Reports Second Quarter 2017 Results
finance.yahoo.com - August 10 at 6:20 AM
-$2.70 Earnings Per Share Expected for Tokai Pharmaceuticals, Inc. (NVUS) This Quarter-$2.70 Earnings Per Share Expected for Tokai Pharmaceuticals, Inc. (NVUS) This Quarter
www.americanbankingnews.com - August 4 at 2:18 PM
Ocera Therapeutics (OCRX) vs. Tokai Pharmaceuticals (NASDAQ:NVUS) Critical AnalysisOcera Therapeutics (OCRX) vs. Tokai Pharmaceuticals (NASDAQ:NVUS) Critical Analysis
www.americanbankingnews.com - July 29 at 12:35 PM
 Analysts Anticipate Tokai Pharmaceuticals, Inc. (NASDAQ:NVUS) to Post -$2.70 Earnings Per Share Analysts Anticipate Tokai Pharmaceuticals, Inc. (NASDAQ:NVUS) to Post -$2.70 Earnings Per Share
www.americanbankingnews.com - July 13 at 8:29 AM
Tokai Pharmaceuticals, Inc. (NASDAQ:NVUS) Receives Consensus Recommendation of "Hold" from AnalystsTokai Pharmaceuticals, Inc. (NASDAQ:NVUS) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - July 12 at 10:21 AM

SEC Filings

Novus Therapeutics (NASDAQ:NVUS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Novus Therapeutics (NASDAQ:NVUS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Novus Therapeutics (NASDAQ NVUS) Stock Chart for Saturday, April, 21, 2018

Loading chart…

This page was last updated on 4/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.